Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Life Sci ; 209: 300-312, 2018 Sep 15.
Article in English | MEDLINE | ID: mdl-30102904

ABSTRACT

AIMS: Previous studies performed by our research group indicated that cytosporone analogues are capable of prevent or repair DNA damages. This work presents the evaluation of the activity of AMS35AA for metastatic murine melanoma cells (B16F10) in experimental model in vitro and, in pre-clinic assay of metastatic melanoma in vivo, using mice lineage C57BL/6. MAIN METHODS: In vitro assays were performed: MTT and comet assay, flow cytometry evaluation, gene expression assay by RT-PCR, qualitative evaluation of cell death using B16F10 cells. In vivo assays: micronucleus and comet assay, splenic phagocytosis, melanoma murine model and histopathological analysis, using mice lineage C57BL/6 (n = 20). KEY FINDINGS: In vitro results performed by MTT assay showed that AMS35AA is cytotoxic for B16F10 cells (p < 0.05). Based on comet assay the genotoxicity of the IC50 was determined (95.83 µg/mL) (p < 0.05). These data were corroborated by flow cytometry analysis after the treatment with AMS35AA, which indicates the cellular death by apoptosis (p < 0.05) and increasing of ATR, p53, p21 and GADD45 gene expressions verified using RT-PCR. With respect to in vivo results, it was observed that AMS35AA did not show genotoxic activity. Data of tumor volume ex vivo indicate reduction of tumor for the treated animals with AMS35AA up to 15.84×, which is superior to Dacarbazina (50 mg/Kg, p.c.; i.p.). SIGNIFICANCE: In summary, the study showed that AMS35AA reveals relevant results regarding to cytotoxicity of B16F10 murine melanoma cells, inducing death by apoptosis via mitochondrial and/or mediated by DNA damages.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Benzofurans/pharmacology , Cell Cycle/drug effects , Cell Proliferation/drug effects , DNA Damage/drug effects , Melanoma, Experimental/drug therapy , Resorcinols/chemistry , Animals , Comet Assay , Male , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Tumor Cells, Cultured
2.
BMC Cancer ; 15: 561, 2015 Jul 31.
Article in English | MEDLINE | ID: mdl-26228542

ABSTRACT

BACKGROUND: A large number of studies are attempting to identify alternative products from natural sources or synthesized compounds that effectively interact with cancer cells without causing adverse effects on healthy cells. Resorcinolic lipids are a class of bioactive compounds that possess anticancer activity and are able to interact with the lipid bilayer. Therefore, the objective of this study was to synthesize a novel resorcinolic lipid and test its biological proprieties. METHODS: We aimed to synthesize a novel resorcinolic lipid belonging to the class of cytosporones, AMS049 (3-Heptyl-4,6-dihydroxy-3H-isobenzofuran-1-one) and to evaluate the toxicity of two concentrations of this lipid (7.5 and 10 mg/kg) by determining its genotoxic, mutagenic, immunomodulatory, and apoptotic effects, as well as any biochemical and histopathological alterations in mice treated with cyclophosphamide. The results were analyzed by ANOVA followed by the Tukey test A . level of significance of p < 0.05 was adopted. RESULTS: The new cytosporone AMS049 was synthesized in only three steps and in satisfactory yields. The results indicate that the compound is neither genotoxic nor mutagenic and does not alter biochemical parameters. The histological alterations observed in the liver and kidneys did not compromise the function of these organs. Histology of the spleen suggested immunomodulation, although no changes were observed in splenic phagocytosis or differential blood cell count. The results also show that AMS049 potentiates the mutagenic effect of the chemotherapy drug cyclophosphamide and that the combination induces apoptosis. CONCLUSION: These facts indicate a potential therapeutic application of this novel cytosporone as an important chemotherapeutic adjuvant.


Subject(s)
Benzofurans/administration & dosage , Benzofurans/chemical synthesis , Cyclophosphamide/administration & dosage , Immunologic Factors/administration & dosage , Immunologic Factors/chemical synthesis , Animals , Apoptosis , Benzofurans/pharmacology , Cyclophosphamide/pharmacology , Drug Synergism , Immunologic Factors/pharmacology , Kidney/drug effects , Kidney/pathology , Liver/drug effects , Liver/pathology , Male , Mice , Spleen/drug effects
3.
J Toxicol Environ Health A ; 76(17): 1003-6, 2013.
Article in English | MEDLINE | ID: mdl-24168035

ABSTRACT

This study assessed the genotoxic and mutagenic potential of diflubenzuron (DFB) insecticide in mice. Mice were divided into five groups: group I: negative control; group II: positive control; group III: 0.3 mg/kg of DFB; group IV: 1 mg/kg of DFB; group V: 3 mg/kg DFB. Peripheral blood was collected for the comet assay and the micronucleus (MN) test. DFB increased incidence of comet formation at all doses tested. A rise in the frequency of MN in mouse peripheral blood was observed 24, 48, and 72 h postexposure at all doses tested. Data demonstrate that DFB exerts genotoxic and mutagenic effects in a dose-dependent manner.


Subject(s)
Diflubenzuron/toxicity , Insecticides/toxicity , Mutagens/toxicity , Animals , Comet Assay , Dose-Response Relationship, Drug , Male , Mice , Micronucleus Tests
SELECTION OF CITATIONS
SEARCH DETAIL